| Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study K Fizazi, M Carducci, M Smith, R Damião, J Brown, L Karsh, P Milecki, ... The Lancet 377 (9768), 813-822, 2011 | 2346 | 2011 |
| Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial MR Smith, F Saad, R Coleman, N Shore, K Fizazi, B Tombal, K Miller, ... The Lancet 379 (9810), 39-46, 2012 | 991 | 2012 |
| A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer DJ Parekh, S Punnen, DD Sjoberg, SW Asroff, JL Bailen, JS Cochran, ... European urology 68 (3), 464-470, 2015 | 438 | 2015 |
| Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image … N Mariados, J Sylvester, D Shah, L Karsh, R Hudes, D Beyer, S Kurtzman, ... International Journal of Radiation Oncology* Biology* Physics 92 (5), 971-977, 2015 | 376 | 2015 |
| Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial DF Penson, AJ Armstrong, R Concepcion, N Agarwal, C Olsson, L Karsh, ... Journal of Clinical Oncology 34 (18), 2098-2106, 2016 | 364 | 2016 |
| Continued benefit to rectal separation for prostate radiation therapy: final results of a phase III trial DA Hamstra, N Mariados, J Sylvester, D Shah, L Karsh, R Hudes, D Beyer, ... International Journal of Radiation Oncology* Biology* Physics 97 (5), 976-985, 2017 | 358 | 2017 |
| Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial SA Boorjian, M Alemozaffar, BR Konety, ND Shore, LG Gomella, ... The Lancet Oncology 22 (1), 107-117, 2021 | 297 | 2021 |
| Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non–muscle-invasive bladder cancer on tumor recurrence: SWOG … EM Messing, CM Tangen, SP Lerner, DM Sahasrabudhe, TM Koppie, ... Jama 319 (18), 1880-1888, 2018 | 215 | 2018 |
| Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer AT Stopeck, K Fizazi, JJ Body, JE Brown, M Carducci, I Diel, Y Fujiwara, ... Supportive Care in Cancer 24, 447-455, 2016 | 211 | 2016 |
| Role of genetic testing for inherited prostate cancer risk: Philadelphia Prostate Cancer Consensus Conference 2017 VN Giri, KE Knudsen, WK Kelly, W Abida, GL Andriole, CH Bangma, ... Journal of Clinical Oncology 36 (4), 414-424, 2018 | 209 | 2018 |
| Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC … A Amin, AZ Dudek, TF Logan, RS Lance, JM Holzbeierlein, JJ Knox, ... Journal for immunotherapy of cancer 3, 1-13, 2015 | 205 | 2015 |
| Intravesical rAd–IFNα/Syn3 for patients with high-grade, Bacillus Calmette-Guerin–refractory or relapsed non–muscle-invasive bladder cancer: a phase II randomized study ND Shore, SA Boorjian, DJ Canter, K Ogan, LI Karsh, TM Downs, ... Journal of Clinical Oncology 35 (30), 3410-3416, 2017 | 183 | 2017 |
| Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer K Fizazi, C Massard, M Smith, M Rader, J Brown, P Milecki, N Shore, ... European urology 68 (1), 42-50, 2015 | 152 | 2015 |
| Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial MR Smith, HI Scher, S Sandhu, E Efstathiou, PN Lara, YY Evan, ... The Lancet Oncology 23 (3), 362-373, 2022 | 128 | 2022 |
| Challenges and recommendations for early identification of metastatic disease in prostate cancer ED Crawford, NN Stone, YY Evan, PJ Koo, SJ Freedland, SF Slovin, ... Urology 83 (3), 664-669, 2014 | 120 | 2014 |
| A randomized phase II trial of sipuleucel-T with concurrent versus sequential abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer EJ Small, RS Lance, TA Gardner, LI Karsh, L Fong, C McCoy, T DeVries, ... Clinical Cancer Research 21 (17), 3862-3869, 2015 | 113* | 2015 |
| Absorbable hydrogel spacer use in prostate radiotherapy: a comprehensive review of phase 3 clinical trial published data LI Karsh, ET Gross, CM Pieczonka, PJ Aliotta, CJ Skomra, LE Ponsky, ... Urology 115, 39-44, 2018 | 111 | 2018 |
| A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. K Fizazi, MA Carducci, MR Smith, R Damião, JE Brown, L Karsh, P Milecki, ... Journal of Clinical Oncology 28 (18_suppl), LBA4507-LBA4507, 2010 | 104 | 2010 |
| A clinician’s guide to next generation imaging in patients with advanced prostate cancer (RADAR III) ED Crawford, PJ Koo, N Shore, SF Slovin, RS Concepcion, SJ Freedland, ... The Journal of urology 201 (4), 682-692, 2019 | 94 | 2019 |
| Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective … JL Gore, M du Plessis, M Santiago‐Jiménez, K Yousefi, DJS Thompson, ... Cancer 123 (15), 2850-2859, 2017 | 81 | 2017 |
